l General Information |
Product Name | Elacridar |
General description | Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor. |
Synonym | N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide; GF120918; GG 918 |
Purity | ≥99%(HPLC) | CAS Number | 143664-11-3 |
Formula | C34H33N3O5 | Molecular Weight | 563.654 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Yellow solid |
Solubility(25℃) | DMSO | ~5mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | GF120918 (Elacridar) is a very potent inhibitor of the ABC transporters MDR-1 (P-gp) and BCRP. GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS. Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in of protein inhibitors. |
l Packaging & Storage |
Packaging | 25mg; 100mg; 500mg |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
